SI3549599T1 - Antibodies against csf-1r - Google Patents

Antibodies against csf-1r

Info

Publication number: SI3549599T1
Authority: SI; Slovenia
Prior art keywords: antibodies against; against csf; csf; antibodies
Prior art date: 2013-08-30

Application number

SI201432048T

Other languages

Slovenian (sl)

Inventor

Graham Craggs

Karine Jeannine Madeleine Herve

Diane Marshall

Original Assignee

UCB Biopharma SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-30

Filing date

2014-08-26

Publication date

2023-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3549599(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-26 Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL

2023-12-29 Publication of SI3549599T1 publication Critical patent/SI3549599T1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)

SI201432048T 2013-08-30 2014-08-26 Antibodies against csf-1r SI3549599T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1315487.7A GB201315487D0 (en)	2013-08-30	2013-08-30	Antibodies
EP19171833.7A EP3549599B1 (en)	2013-08-30	2014-08-26	Antibodies against csf-1r

Publications (1)

Publication Number	Publication Date
SI3549599T1 true SI3549599T1 (en)	2023-12-29

Family

ID=49397073

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201431235T SI3038643T1 (en)	2013-08-30	2014-08-26	Antibodies against csf-1r
SI201432048T SI3549599T1 (en)	2013-08-30	2014-08-26	Antibodies against csf-1r

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201431235T SI3038643T1 (en)	2013-08-30	2014-08-26	Antibodies against csf-1r

Country Status (39)

Country	Link
US (2)	US9908939B2 (en)
EP (3)	EP4282881A3 (en)
JP (3)	JP6632075B2 (en)
KR (1)	KR102303130B1 (en)
CN (2)	CN112321711B (en)
AR (1)	AR097464A1 (en)
AU (1)	AU2014314304B2 (en)
BR (1)	BR112016004324B1 (en)
CA (1)	CA2922240C (en)
CL (1)	CL2016000438A1 (en)
CY (1)	CY1121964T1 (en)
DK (2)	DK3038643T3 (en)
EA (1)	EA036255B1 (en)
ES (2)	ES2733735T3 (en)
FI (1)	FI3549599T3 (en)
GB (1)	GB201315487D0 (en)
HK (1)	HK1220142A1 (en)
HR (2)	HRP20231264T1 (en)
HU (2)	HUE064437T2 (en)
IL (1)	IL244043B (en)
LT (2)	LT3038643T (en)
MA (2)	MA38930A1 (en)
MX (1)	MX2016002166A (en)
MY (1)	MY172484A (en)
NZ (1)	NZ717399A (en)
PE (2)	PE20201067A1 (en)
PH (1)	PH12016500275A1 (en)
PL (2)	PL3038643T3 (en)
PT (2)	PT3038643T (en)
RS (2)	RS64784B1 (en)
SG (1)	SG11201601151PA (en)
SI (2)	SI3038643T1 (en)
TN (1)	TN2016000067A1 (en)
TR (1)	TR201909478T4 (en)
TW (1)	TWI531582B (en)
UA (1)	UA118354C2 (en)
UY (1)	UY35718A (en)
WO (1)	WO2015028455A1 (en)
ZA (1)	ZA201601437B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201315487D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
CA2987146A1 (en) *	2015-05-27	2016-12-01	Ucb Biopharma Sprl	Method for the treatment of neurological disease
CN107810012A (en) *	2015-06-02	2018-03-16	豪夫迈·罗氏有限公司	Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34
CA3026477A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 antibodies
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018213665A1 (en)	2017-05-19	2018-11-22	Syndax Pharmaceuticals, Inc.	Combination therapies
GB201803226D0 (en) *	2018-02-28	2018-04-11	Ultrahuman Twelve Ltd	CSF1R Binding agents
CN108948198B (en) *	2018-07-18	2020-09-01	博奥信生物技术（南京）有限公司	Anti-human CSF-1R monoclonal antibody and application thereof
CN109096397B (en) *	2018-07-18	2019-04-16	博奥信生物技术（南京）有限公司	A kind of anti-human CSF-1R monoclonal antibody and application
EP3894014A4 (en) *	2018-12-13	2022-04-20	Development Center for Biotechnology	Anti-human csf-1r antibody and uses thereof
CN113939539B (en) *	2019-05-15	2024-06-04	博奥信生物技术（南京）有限公司	Antibodies that bind CSF-1R and uses thereof
JP2023506779A (en) *	2019-12-09	2023-02-20	シンダックスファーマシューティカルズ，インコーポレイテッド	Antibodies for treating chronic graft-versus-host disease
US20230203170A1 (en) *	2019-12-24	2023-06-29	Adagene (Suzhou) Limited	Anti-CSF1R Molecules and Use Thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (en)	1987-07-01	1987-07-01	Novo Industri As	immobilization
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
FR2716640B1 (en)	1994-02-28	1996-05-03	Procedes Machines Speciales	Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
EP1570267B1 (en)	2002-12-03	2011-10-12	UCB Pharma, S.A.	Assay for identifying antibody producing cells
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
CA2527020A1 (en)	2003-07-01	2005-01-13	Celltech R & D Limited	Modified antibody fab fragments
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (en) *	2003-09-10	2005-11-02	Warner Lambert Co	ANTIBODIES DIRECTED TO M-CSF
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
MY146381A (en) *	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
LT2188313T (en) *	2007-08-21	2018-02-26	Amgen, Inc.	Human c-fms antigen binding proteins
ES2667729T3 (en)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusions of antibodies with double specificity
JO3240B1 (en) *	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	Inhibitors of c-fms Kinase
MX2010009894A (en) *	2008-03-14	2011-02-22	Transgene Sa	Antibody against the csf-1 r.
US8470977B2 (en) *	2008-03-14	2013-06-25	Transgene S.A.	Antibody against the CSF-1R
JP6063122B2 (en)	2008-09-26	2017-01-18	ユセベファルマソシエテアノニム	Biological products
US20120283415A1 (en)	2009-09-10	2012-11-08	Ucb Pharma S.A.	Multivalent Antibodies
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
CN105218672A (en) *	2009-12-10	2016-01-06	霍夫曼-拉罗奇有限公司	Preferentially in conjunction with the antibody and uses thereof of people CSF1R extracellular domain 4
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
US9169323B2 (en)	2010-03-05	2015-10-27	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R
KR101647871B1 (en) *	2010-03-05	2016-08-11	에프. 호프만-라 로슈 아게	Antibodies against human csf-1r and uses thereof
AR080698A1 (en) *	2010-04-01	2012-05-02	Imclone Llc	ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
EP2566517B1 (en)	2010-05-04	2018-10-24	Five Prime Therapeutics, Inc.	Antibodies that bind csf1r
CA2853889A1 (en) *	2011-12-15	2013-06-20	F. Hoffmann-La Roche Ag	Antibodies against human csf-1r and uses thereof
GB201315487D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
GB201315486D0 (en)	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies

2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/en active
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/en active IP Right Grant
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/en unknown
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/en active Pending
- 2014-08-26 MA MA38930A patent/MA38930A1/en unknown
- 2014-08-26 SI SI201431235T patent/SI3038643T1/en unknown
- 2014-08-26 PT PT14755668T patent/PT3038643T/en unknown
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/en unknown
- 2014-08-26 ES ES14755668T patent/ES2733735T3/en active Active
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/en active
- 2014-08-26 SI SI201432048T patent/SI3549599T1/en unknown
- 2014-08-26 CN CN202011009068.8A patent/CN112321711B/en active Active
- 2014-08-26 RS RS20230962A patent/RS64784B1/en unknown
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/en active
- 2014-08-26 ES ES19171833T patent/ES2965207T3/en active Active
- 2014-08-26 PL PL14755668T patent/PL3038643T3/en unknown
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/en active Active
- 2014-08-26 MA MA44922A patent/MA44922B1/en unknown
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/en unknown
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/en active Active
- 2014-08-26 CA CA2922240A patent/CA2922240C/en active Active
- 2014-08-26 EA EA201690503A patent/EA036255B1/en not_active IP Right Cessation
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/en unknown
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/en unknown
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/en active Application Filing
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/en active Active
- 2014-08-26 MX MX2016002166A patent/MX2016002166A/en active IP Right Grant
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/en unknown
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 PT PT191718337T patent/PT3549599T/en unknown
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/en unknown
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/en active IP Right Grant
- 2014-08-26 RS RS20190833A patent/RS59019B1/en unknown
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/en unknown
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/en unknown
- 2014-08-26 UA UAA201601175A patent/UA118354C2/en unknown
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/en active Active
- 2014-08-26 DK DK19171833.7T patent/DK3549599T5/en active
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-27 AR ARP140103206A patent/AR097464A1/en unknown
- 2014-08-29 UY UY35718A patent/UY35718A/en not_active Application Discontinuation
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275A1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/en unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
- 2016-07-15 HK HK16108335.9A patent/HK1220142A1/en unknown
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
2019
- 2019-06-12 HR HRP20191051TT patent/HRP20191051T1/en unknown
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/en unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/en active Active
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/en active Pending

Also Published As

Publication number	Publication date
AU2014314304A1 (en)	2016-03-17
AU2014314304B2 (en)	2019-12-05
LT3038643T (en)	2019-07-25
FI3549599T3 (en)	2023-10-31
TWI531582B (en)	2016-05-01
CY1121964T1 (en)	2020-10-14
HRP20231264T1 (en)	2024-02-02
PH12016500275B1 (en)	2016-05-02
EP4282881A2 (en)	2023-11-29
SG11201601151PA (en)	2016-03-30
WO2015028455A1 (en)	2015-03-05
DK3549599T5 (en)	2024-09-02
PT3549599T (en)	2023-11-21
UA118354C2 (en)	2019-01-10
DK3549599T3 (en)	2023-10-30
TW201512221A (en)	2015-04-01
RS64784B1 (en)	2023-11-30
CN112321711B (en)	2024-11-08
US20160200821A1 (en)	2016-07-14
LT3549599T (en)	2023-11-10
PL3549599T3 (en)	2024-03-04
JP2016529266A (en)	2016-09-23
PH12016500275A1 (en)	2016-05-02
HUE064437T2 (en)	2024-03-28
JP2020005652A (en)	2020-01-16
JP6632075B2 (en)	2020-01-15
PT3038643T (en)	2019-07-25
ZA201601437B (en)	2018-08-29
BR112016004324B1 (en)	2024-01-16
EP4282881A3 (en)	2024-02-21
MX2016002166A (en)	2016-06-23
PE20160528A1 (en)	2016-05-21
ES2965207T3 (en)	2024-04-11
RS59019B1 (en)	2019-08-30
KR102303130B1 (en)	2021-09-16
MA44922A1 (en)	2019-08-30
BR112016004324A2 (en)	2017-10-24
US10421814B2 (en)	2019-09-24
EA036255B1 (en)	2020-10-20
TN2016000067A1 (en)	2017-07-05
CL2016000438A1 (en)	2016-11-11
CA2922240C (en)	2023-09-05
MA44922B1 (en)	2020-06-30
IL244043B (en)	2021-01-31
GB201315487D0 (en)	2013-10-16
PE20201067A1 (en)	2020-10-19
HUE045672T2 (en)	2020-01-28
EA201690503A1 (en)	2016-06-30
ES2733735T3 (en)	2019-12-02
JP2022002523A (en)	2022-01-11
KR20160044018A (en)	2016-04-22
DK3038643T3 (en)	2019-06-24
EP3549599A1 (en)	2019-10-09
HRP20191051T1 (en)	2019-09-06
MA38930A1 (en)	2017-12-29
TR201909478T4 (en)	2019-07-22
US20180162947A1 (en)	2018-06-14
PL3038643T3 (en)	2019-11-29
EP3038643A1 (en)	2016-07-06
SI3038643T1 (en)	2019-08-30
HK1220142A1 (en)	2017-04-28
EP3038643B1 (en)	2019-05-01
JP7195237B2 (en)	2022-12-23
MY172484A (en)	2019-11-26
EP3549599B1 (en)	2023-09-06
US9908939B2 (en)	2018-03-06
CN105658236B (en)	2021-03-19
NZ717399A (en)	2021-12-24
IL244043A0 (en)	2016-04-21
CN105658236A (en)	2016-06-08
UY35718A (en)	2015-03-27
CA2922240A1 (en)	2015-03-05
AR097464A1 (en)	2016-03-16
CN112321711A (en)	2021-02-05